Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of novel spike-in controls for quantitative chromatin-associated protein profiling

Award Number: R44DE029633
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/13/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Development of novel spike-in controls for quantitative chromatin-associated protein profiling - PROJECT SUMMARY Alterations in chromatin regulators are associated with diverse human pathologies. The ability to quantitatively assess these factors in healthy and diseased cells is essential to accelerate the development of therapeutics targeting epigenetic regulation (a growing area of study, with many candidates already in clinical trials). However, ChIP-Seq, the most widely-used approach to map the genomic location of Chromatin Associated Proteins (ChAPs), is often limited by poor resolution, sensitivity, and reliability. Dr. Steven Henikoff’s group recently developed CUT&RUN (Cleavage Under Targets and Released Using Nuclease), a new mapping approach with vastly improved assay performance vs. ChIP-Seq. CUT&RUN uses ChAP-targeting antibodies to locally tether protein A-micrococcal nuclease (pA-MNase) to chromatin in intact nuclei, followed by controlled MNase activation to cleave nearby DNA. Sequencing of the subsequently released DNA fragments yields precise target localization profiles using fractions (vs. ChIP-Seq) of the required cellular input (100-fold less) and sequencing depth (>10-fold less). The efficiency of this method could now enable pre-clinical applications in a high-throughput format, such as quantifying the genome-wide effects of epigenetic therapeutics. However, delivering on such promise will require the development of quantitative spike-ins. In this Fast-Track SBIR proposal, EpiCypher® is partnering with Dr. Kami Ahmad of the Henikoff lab to develop quantitative spike-in controls for ChAPs using CUT&RUN (ChAP-CUT&RUN). EpiCypher has recently developed the application of DNA-barcoded recombinant designer nucleosomes (dNucs) as quantitative spike-in controls for histone post-translational modification (PTM) ChIP studies (i.e. SNAP-ChIP®). However, there are no tools to normalize mapping data for ChAPs, which make up the largest segment of the ChIP-Seq market. The innovation of this project is the engineering of DNA-barcoded dNucs that contain either: 1) a ChAP epitope; or 2) a Short Peptide Tag (SPT; e.g. FLAG) fused to the N-terminus of histone H3. These can then be used to capture ChAP- or SPT-specific antibodies (both commonly used for ChAP mapping studies) in a CUT&RUN workflow. In Aim 1 (Phase I), we will develop a set of DNA-barcoded dNuc spike-ins for quantitative analysis of ChAPs (e.g. CTCF [transcription factor] and BRD4 [chromatin interactor]). Phase I will be successfully completed when we use these dNucs in CUT&RUN for quantitative sample normalization. In Aim 2 (Phase II), we will expand / scale manufacturing of ChAP-CUT&RUN spike-in control panels and apply these reagents to establish robust workflows for quantitative sample normalization genome- wide. In Aim 3 we will develop and externally validate ChAP-CUT&RUN beta kits. We envision ChAP-CUT&RUN will become one of the most widely used assays in the epigenetics field (given the vast gain in assay metrics vs. ChIP-Seq), with the potential to open new markets for the routine analysis of limited (i.e. precious) clinical samples.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	EPICYPHER, INC.	6 DAVIS DR	DURHAM	NC	27709	DURHAM	USA	Oral Diseases and Disorders Research	000	3	5/28/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $978,257 )
2021	2021	EPICYPHER, INC.	6 DAVIS DR	DURHAM	NC	27709	DURHAM	USA	Oral Diseases and Disorders Research	000	3	7/15/2021	NON-COMPETING CONTINUATION	$978,257
2021	2019	EPICYPHER, INC.	6 DAVIS DR	DURHAM	NC	27709	DURHAM	USA	Oral Diseases and Disorders Research	001	1	7/17/2021	NEW	$0
														Subtotal = $978,257

Issue Date FY: 2020 ( Subtotal = $978,257 )
2020	2020	EPICYPHER, INC.	6 DAVIS DR	DURHAM	NC	27709	DURHAM	USA	Oral Diseases and Disorders Research	000	2	8/28/2020	EXTENSION WITH OR WITHOUT FUNDS	$978,257
														Subtotal = $978,257

Issue Date FY: 2019 ( Subtotal = $259,086 )
2019	2019	EPICYPHER, INC.	6 DAVIS DR	DURHAM	NC	27709	DURHAM	USA	Oral Diseases and Disorders Research	000	1	9/13/2019	NEW	$259,086
														Subtotal = $259,086

Grand Total All Awards = $2,215,600

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of novel spike-in controls for quantitative chromatin-associated protein profiling

Award Number: R44DE029633

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/13/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer